VINORELBINE PIERRE FABRE vinorelbine 20mg (as tartrate) capsule blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

vinorelbine tartrate, Quantity: 27.7 mg (Equivalent: vinorelbine, Qty 20 mg)

Available from:

Pierre Fabre Australia Pty Ltd

Pharmaceutical form:

Capsule, soft

Composition:

Excipient Ingredients: ethanol; purified water; glycerol; macrogol 400; Gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal

Administration route:

Oral

Units in package:

1 tablet

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Non-small cell lung cancer: VINORELBINE PIERRE FABRE is indicated for the first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,Breast cancer: VINORELBINE PIERRE FABRE is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

Product summary:

Visual Identification: Light brown soft capsule printed N20.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2005-05-31